|Systematic (IUPAC) name|
|Trade names||Myrbetriq (US), Betanis (Japan), Betmiga (EU)|
|Licence data||EMA:, US FDA:|
|Metabolism||Hepatic via (direct) glucuronidation, amide hydrolysis, and minimal oxidative metabolism in vivo by CYP2D6 and CYP3A4. Some involvement of butylcholinesterase|
|Excretion||Urine (55%), faeces (34%)|
|Mol. mass||396.506 g/mol|
Mirabegron (formerly YM-178, trade name Myrbetriq, Betmiga in Spain) is a drug for the treatment of overactive bladder. It was developed by Astellas Pharma and was approved in the United States in July 2012.
Very common (>10% incidence) adverse effects include:
- Elevated blood pressure
Common (1-10% incidence) adverse effects include:
- Xerostomia (dry mouth)
- Urinary tract infection (UTI)
- Back pain
- Upper respiratory tract infection (URTI)
- Tachycardia (high heart rate)
- Abdominal pain
- Neoplasms (cancers)
Rare (<1% incidence) adverse effects include:
- Blurred vision
- Dyspepsia (indigestion)
- Abdominal distension
- Elevations in liver enzymes (GGT, AST, ALT & LDH)
- Renal and urinary disorders (e.g., nephrolithiasis, bladder pain)
- Reproductive system disorders (e.g., vulvovaginal pruritis, vaginal infection)
- Skin and subcutaneous tissue disorders (e.g., urticaria, leukocytoclastic vasculitis, rash, pruritus, purpura, lip edema)
- Stevens-Johnson syndrome associated with increased serum ALT, AST and bilirubin
- Urinary retention
- "mirabegron (Rx) - Myrbetriq". Medscape Reference. WebMD. Retrieved 17 November 2013.
- Gras, J (2012). "Mirabegron for the treatment of overactive bladder". Drugs of today (Barcelona, Spain : 1998) 48 (1): 25–32.
- Sacco E, Bientinesi R, et al. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence. Expert Opin Drug Discov. 2014 Apr;9(4):433-48. doi: 10.1517/17460441.2014.892923. Epub 2014 Feb 22.PMID 2455903
- "New Drug Approvals 2012 - Pt. XIV - Mirabegron (MyrbetriqTM)".
- "MYRBETRIQ (mirabegron) tablet, film coated, extended release [Astellas Pharma US, Inc.]". DailyMed. Astellas Pharma US, Inc. September 2012. Retrieved 17 November 2013.
- "Betmiga 25mg & 50mg prolonged-release tablets". electronic Medicines Compendium. Astellas Pharma Ltd. 22 February 2013. Retrieved 17 November 2013.
- Sacco, E.; Bientinesi, R. (2012). "Mirabegron: A review of recent data and its prospects in the management of overactive bladder". Therapeutic Advances in Urology 4 (6): 315–24.